Exploratory Study of Novel MSLN CAR-T Cell Therapy in Patients With MSLN-positive Advanced Refractory Solid Tumors

Phase 1 Withdrawn Shanghai Pudong Hospital UTC Therapeutics Inc. · collab

NaSingle-groupOpen-labelTreatment

Summary

This is a single-arm, open-label, exploratory clinical study to evaluate the safety and efficacy of novel Mesothelin CAR-T in patients with Mesothelin-positive advanced refractory solid tumors.

Timeline

Start: 2021-04-02
Primary completion: 2025-04-30
Completion: 2026-04-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Anti-mesothelin CAR-T cells	Cell therapy	—	Intravenous
Background	Cyclophosphamide	Other / unclassified	60 mg/kg	Intravenous
Background	Fludarabine	Small molecule	25 mg/m2	Intravenous

Indications

No indication recorded.